Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H42O9 |
Molecular Weight | 534.6384 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 12 / 12 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@H](O)[C@H](O)[C@@H](C)O1)O[C@H]2CC[C@]3(C=O)[C@@]4([H])CC[C@]5(C)[C@H](CC[C@]5(O)[C@]4([H])CC[C@]3(O)C2)C6=CC(=O)OC6
InChI
InChIKey=QBILRDAMJUPXCX-AGAUEGNUSA-N
InChI=1S/C29H42O9/c1-16-25(33)22(31)12-24(37-16)38-18-3-8-27(15-30)20-4-7-26(2)19(17-11-23(32)36-14-17)6-10-29(26,35)21(20)5-9-28(27,34)13-18/h11,15-16,18-22,24-25,31,33-35H,3-10,12-14H2,1-2H3/t16-,18+,19-,20+,21-,22+,24+,25-,26-,27+,28+,29+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26384484Curator's Comment: Description was created based on several sources, including
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26384484
Curator's Comment: Description was created based on several sources, including
Helveticoside is a well-known digitalis-like cardiac glycosidic constituent of ELA (Lepidium apetalum). It increased atrial stroke volume and pulse pressure without changes in cAMP efflux. Helveticoside inhibited lung cancer cell line A549 with IC50 35 nm.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL392 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26384484 |
35.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m5937
Created by
admin on Sat Dec 16 10:09:36 GMT 2023 , Edited by admin on Sat Dec 16 10:09:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
441860
Created by
admin on Sat Dec 16 10:09:36 GMT 2023 , Edited by admin on Sat Dec 16 10:09:36 GMT 2023
|
PRIMARY | |||
|
630-64-8
Created by
admin on Sat Dec 16 10:09:36 GMT 2023 , Edited by admin on Sat Dec 16 10:09:36 GMT 2023
|
PRIMARY | |||
|
52OAE3C457
Created by
admin on Sat Dec 16 10:09:36 GMT 2023 , Edited by admin on Sat Dec 16 10:09:36 GMT 2023
|
PRIMARY | |||
|
211-140-9
Created by
admin on Sat Dec 16 10:09:36 GMT 2023 , Edited by admin on Sat Dec 16 10:09:36 GMT 2023
|
PRIMARY | |||
|
DTXSID001317694
Created by
admin on Sat Dec 16 10:09:36 GMT 2023 , Edited by admin on Sat Dec 16 10:09:36 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD